Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57769 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL57753 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL16861355 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL16861356 | 1.00 | DPP4 (0.41) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| Hydrochloric Acid SCHEMBL29511344 | 0.99 | DPP4 (0.40) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL14567882 | 0.88 | DPP4 (0.42) | DPP4GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL12203122 | 0.86 | DPP4 (0.35) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL90441 | 0.86 | DPP4 (0.35) | DPP4TUBB1GLO1CYP2C9CYP2D6 | |
| SCHEMBL16169554 | 0.86 | TUBB1 (0.34) | TUBB1GLO1CYP2C9CYP2D6CYP2C19 | |
| SCHEMBL14210216 | 0.86 | TUBB1 (0.34) | TUBB1GLO1CYP2C9CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051329-A | Hamiltrin derivatives and antibody drug complexes thereof | 大日本住友制药株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-111032676-A | Antibody drug complex comprising a hemiasterlin derivative | 大日本住友制药株式会社 | 2020-04-17 | — | — | CN | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | DPP4 4723/4885TUBB1 1330/4885GLO1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.